FDA will accelerate review of Usona’s drug application for psilocybin
The Food and Drug Administration will fast track review of Fitchburg-based Usona Institute’s application for using psilocybin to treat severe depression.
To access this post, you must purchase Premium Subscription - Daily Email and Full Website Access.